We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biotech Companies Fight Aging at the Cellular Level

By Biotechdaily staff writers
Posted on 16 Apr 2007
Exclusively licensed from the Geron Corp. More...
(Menlo Park, CA, USA), a new product, TA-65, is the world's first telomerase activator.

Telomerase Activation Sciences, Inc. (TA Sciences; New York, NY, USA) announced its license with Geron to develop and market non-therapeutic products using Geron's small molecule telomerase activators. TA Sciences has recently opened the TA Sciences Center in New York City, where customers can purchase TA Sciences' first product, a nutraceutical containing the telomerase-activating agent TA-65.

"TA Sciences welcomes our first customers and the launch of the world's first telemetries-activator product,” said Noel Thomas Patton, founder of TA Sciences. "A natural consequence of aging is the shortening of telomeres [caps of DNA located at the ends of all chromosomes], which ultimately results in loss of cell function. TA-65 offers the potential of reducing or reversing telomere shortening and battles tissue and organ degeneration by rejuvenating aging cells.”

TA-65 is the result of vigorous scientific research that began at Geron in 1992. The response from the scientific community to the news of TA Sciences' launch has been very enthusiastic. "Telomerase Activation is the single most promising approach to reversing the effects of aging,” said Michael Fossel, M.D., Ph.D., clinical professor of medicine at Michigan State University (East Lansing, MI, USA), and specialist on aging and age- related clinical disease.

Moreover, Dr. William H. Andrews, founder of Sierra Sciences, LLC (Reno, NV, USA), and one of the principal discoverers of the telomerase genes, commented, "Cleopatra, Ponce de Leon, and untold others throughout the ages have searched for the secrets of youth. That search has been futile, until now: Telomerase Activation is the first and only scientifically sound way to approach anti-aging. TA-65 is the first product in history that has been proven to slow or reverse cellular aging.”

On April 30, 2007, TA Sciences plans to publish the results of the pivotal 2005 Anti-Aging trial, which is the first ever human-clinical trial of a telomerase activator. This trial shows statistical verification of the anti-aging benefits of telomerase activation.


Related Links:
Geron
Telomerase Activation Sciences

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.